{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Serous+Epithelial+Ovarian+Cancer&page=2",
    "query": {
      "condition": "Serous Epithelial Ovarian Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Serous+Epithelial+Ovarian+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T17:09:22.817Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05243524",
      "title": "Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-resistant Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Maveropepimut-S",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide 50mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2022-08-05",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05243524"
    },
    {
      "nct_id": "NCT00520013",
      "title": "Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer",
        "Papillary Serous Mullerian Tumor",
        "Clear Cell Mullerian Tumor"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2007-08",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-07-27",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00520013"
    },
    {
      "nct_id": "NCT05613088",
      "title": "A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Ovarian"
      ],
      "interventions": [
        {
          "name": "MORAb-202",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin (PLD)",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 106,
      "start_date": "2023-02-01",
      "completion_date": "2025-09-10",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 10,
      "location_summary": "Sacramento, California • San Francisco, California • Whittier, California + 7 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05613088"
    },
    {
      "nct_id": "NCT07303894",
      "title": "A Study of Isoquercetin in People With Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Epithelial Ovarian Cancer",
        "Serous Ovarian Tumor"
      ],
      "interventions": [
        {
          "name": "Isoquercetin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-01-22",
      "completion_date": "2032-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 8,
      "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07303894"
    },
    {
      "nct_id": "NCT00217529",
      "title": "Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2004-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-09-21",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 3,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217529"
    },
    {
      "nct_id": "NCT05231122",
      "title": "Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Clear Cell Adenocarcinoma",
        "Platinum-Sensitive Ovarian Carcinoma",
        "Recurrent Endometrial Serous Adenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Fallopian Tube Endometrioid Adenocarcinoma",
        "Recurrent Fallopian Tube Serous Adenocarcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Ovarian Clear Cell Adenocarcinoma",
        "Recurrent Ovarian Endometrioid Adenocarcinoma",
        "Recurrent Ovarian Serous Adenocarcinoma",
        "Recurrent Platinum-Resistant Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma",
        "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma",
        "Recurrent Primary Peritoneal Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Anti-CD40 Agonist Monoclonal Antibody CDX-1140",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2024-03-12",
      "completion_date": "2027-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Houston, Texas",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05231122"
    },
    {
      "nct_id": "NCT05891197",
      "title": "A Biomarker Screening Protocol for Participants With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
        "Advanced Breast Cancer",
        "Advanced Lung Carcinoma",
        "NSCLC",
        "NSCLC, Recurrent",
        "NSCLC Stage IV",
        "Relapsed Cancer",
        "Relapse/Recurrence",
        "Recurrent Breast Cancer",
        "Recurrent NSCLC",
        "Platinum-resistant Ovarian Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Endometrioid Tumor",
        "High Grade Serous Carcinoma",
        "Ovarian Epithelial Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Lyell Immunopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-05-19",
      "completion_date": "2025-02-05",
      "has_results": false,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 1,
      "location_summary": "Rocky Mount, North Carolina",
      "locations": [
        {
          "city": "Rocky Mount",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891197"
    },
    {
      "nct_id": "NCT00004221",
      "title": "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Ovarian Mixed Epithelial Tumor",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Primary Peritoneal Carcinoma",
        "Stage III Ovarian Cancer",
        "Undifferentiated Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "1999-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-08-09",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004221"
    },
    {
      "nct_id": "NCT00262847",
      "title": "Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Malignant Ovarian Mixed Epithelial Tumor",
        "Ovarian Brenner Tumor",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer",
        "Undifferentiated Fallopian Tube Carcinoma",
        "Undifferentiated Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1873,
      "start_date": "2005-09",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 614,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262847"
    },
    {
      "nct_id": "NCT00939809",
      "title": "A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Carcinoma",
        "Malignant Ovarian Mixed Epithelial Tumor",
        "Ovarian Brenner Tumor",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Primary Peritoneal Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Undifferentiated Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Urokinase-Derived Peptide A6",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2009-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-06-10T17:09:22.817Z",
      "location_count": 16,
      "location_summary": "Augusta, Georgia • Iowa City, Iowa • Omaha, Nebraska + 11 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00939809"
    }
  ]
}